Published in J Clin Pharmacol on June 01, 2003
The systemic theory of living systems and relevance to CAM: the theory (Part III). Evid Based Complement Alternat Med (2005) 1.25
Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Br J Gen Pract (2006) 1.03
Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2005) 0.91
Alternative medicine in atrial fibrillation treatment-Yoga, acupuncture, biofeedback and more. J Thorac Dis (2015) 0.91
Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease. Pharmacogn Rev (2010) 0.87
The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. Eur J Heart Fail (2008) 0.86
[Pharmacokinetic drug interactions by herbal drugs: Critical evaluation and clinical relevance]. Wien Med Wochenschr (2010) 0.82
Neurologically Potent Molecules from Crataegus oxyacantha; Isolation, Anticholinesterase Inhibition, and Molecular Docking. Front Pharmacol (2017) 0.75
Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review. Syst Rev (2012) 0.75
Therapeutic Risk and Benefits of Concomitantly Using Herbal Medicines and Conventional Medicines: From the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management. Evid Based Complement Alternat Med (2017) 0.75
Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med (2007) 7.15
Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol (2009) 4.03
Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol (2010) 3.63
Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation (2005) 3.48
Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol (2011) 3.06
Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J (2002) 2.95
Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol (2005) 2.38
The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol (2008) 2.37
Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol (2003) 2.35
Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation (2005) 2.12
HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant (2013) 1.96
Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension (2011) 1.93
The development of aortic insufficiency in left ventricular assist device-supported patients. Circ Heart Fail (2010) 1.87
The cost of medical management in advanced heart failure during the final two years of life. J Card Fail (2008) 1.71
Photoinstability of S-nitrosothiols during sampling of whole blood: a likely source of error and variability in S-nitrosothiol measurements. Clin Chem (2008) 1.48
Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation (2010) 1.44
Impact of patient financial incentives on participation and outcomes in a statin pill-splitting program. Am J Manag Care (2007) 1.42
Pharmacologic management of heart failure caused by systolic dysfunction. Am Fam Physician (2008) 1.40
Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health (2006) 1.38
Effect of pharmacy practice residency training on residents' knowledge of and interest in clinical research. Am J Health Syst Pharm (2007) 1.32
Vitamin D and cardiovascular disease. Pharmacotherapy (2009) 1.28
Hemodynamic and exercise performance with pulsatile and continuous-flow left ventricular assist devices. Circulation (2007) 1.21
Device exchange after primary left ventricular assist device implantation: indications and outcomes. Ann Thorac Surg (2012) 1.18
Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transplant (2010) 1.11
Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol (2002) 1.08
Barriers to constraining health care cost growth. Health Aff (Millwood) (2004) 1.07
Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatr Pulmonol (2010) 1.07
Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failure. Am J Cardiol (2005) 1.05
Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J (2004) 1.05
The prevalence and pattern of complementary and alternative supplement use in individuals with chronic heart failure. J Card Fail (2005) 1.04
Controversies in the use of beta blockers in heart failure. Congest Heart Fail (2003) 0.95
Effect of tablet splitting on serum cholesterol concentrations. Ann Pharmacother (2002) 0.94
Coffee, tea, caffeine intake, and risk of adult glioma in three prospective cohort studies. Cancer Epidemiol Biomarkers Prev (2010) 0.94
Pharmacist-prepared dispensing guidelines for drugs used in clinical research. Am J Health Syst Pharm (2012) 0.94
Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects. J Clin Pharmacol (2002) 0.92
Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant (2004) 0.91
Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA (2006) 0.89
Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial. Eur J Heart Fail (2009) 0.89
Delayed sternal closure does not increase late infection risk in patients undergoing left ventricular assist device implantation. J Heart Lung Transplant (2012) 0.89
Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation. Ann Thorac Surg (2013) 0.88
The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. Eur J Heart Fail (2008) 0.86
Vardenafil treatment for erectile dysfunction. Ann Pharmacother (2004) 0.86
Heart failure prognostic models: why bother? Circ Heart Fail (2012) 0.85
Neurocognitive assessments in advanced heart failure patients receiving continuous-flow left ventricular assist devices. J Heart Lung Transplant (2009) 0.84
Accuracy of the avosure PT pro system compared with a hospital laboratory standard. Ann Pharmacother (2002) 0.83
Relation of body mass index to mortality after development of heart failure due to acute coronary syndrome. Am J Cardiol (2009) 0.82
Baseline albumin is associated with worsening renal function in patients with acute decompensated heart failure receiving continuous infusion loop diuretics. Pharmacotherapy (2013) 0.81
Prognostic impact of the addition of peak oxygen consumption to the Seattle Heart Failure Model in a transplant referral population. J Heart Lung Transplant (2012) 0.81
Right-sided heart failure: diagnosis and treatment strategies. Curr Treat Options Cardiovasc Med (2008) 0.80
Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension. Vasc Health Risk Manag (2012) 0.80
The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother (2004) 0.80
Effects of hawthorn on cardiac remodeling and left ventricular dysfunction after 1 month of pressure overload-induced cardiac hypertrophy in rats. Cardiovasc Drugs Ther (2008) 0.80
Loading, pretreatment, and interindividual variability issues with clopidogrel dosing. Circulation (2005) 0.80
Left ventricular assist device management in patients chronically supported for advanced heart failure. Curr Opin Cardiol (2011) 0.80
In vitro assessment of prosthesis type and pressure recovery characteristics: Doppler echocardiography overestimation of bileaflet mechanical and bioprosthetic aortic valve gradients. J Thorac Cardiovasc Surg (2012) 0.79
Safety and efficacy of atorvastatin in heart transplant recipients. J Heart Lung Transplant (2002) 0.79
Diagnosis and management of right-sided heart failure in subjects supported with left ventricular assist devices. Curr Treat Options Cardiovasc Med (2010) 0.79
CRT-D therapy in heart failure: how much do NYHA class IV patients benefit? J Cardiovasc Electrophysiol (2006) 0.78
Use of laryngeal mask airway in flexible bronchoscopy in infants and children. Pediatr Pulmonol (2005) 0.78
Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol (2003) 0.78
Impact of serial changes in cardiac hemodynamics on exercise performance in patients with heart failure due to ischemic and nonischemic cardiomyopathy. Am J Cardiol (2003) 0.78
Heart failure assessment at the community pharmacy level: a feasibility pilot study. J Am Pharm Assoc (2003) (2014) 0.77
Identification of device malfunction in patients supported with the HeartMate XVE left ventricular assist system. ASAIO J (2007) 0.77
Brain natriuretic peptide predicts serious cardiac allograft rejection independent of hemodynamic measurements. J Heart Lung Transplant (2005) 0.77
Prevention of percutaneous driveline infection after left ventricular assist device implantation: prophylactic antibiotics are not necessary. ASAIO J (2013) 0.77
A web application for self-monitoring improves symptoms in chronic systolic heart failure. Telemed J E Health (2015) 0.77
The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease. Pediatr Pulmonol (2010) 0.76
Nesiritide for acute decompensated heart failure: does the benefit justify the risk? Curr Cardiol Rep (2007) 0.76
Food: an unrecognized source of loop diuretic resistance. Pharmacotherapy (2004) 0.76
Heart failure: clinical problem and management issues. Prim Care (2013) 0.76
Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia. Am Heart J (2006) 0.76
Statistical methods for test and biomarker evaluation studies: a clinical chemistry series. Clin Chem (2012) 0.76
3-HMG-Coenzyme A reductase inhibition and extracellular matrix gene expression in the pressure-overloaded rat heart. J Cardiovasc Pharmacol (2006) 0.76
Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. Circ Heart Fail (2012) 0.76
Treatment of heart failure with preserved ejection fraction. Pharmacotherapy (2011) 0.76
Nesiritide--not verified. N Engl J Med (2005) 0.75
Sex matters, but to what clinical avail? Circ Heart Fail (2009) 0.75
Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. J Clin Pharmacol (2010) 0.75
The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. J Cardiovasc Pharmacol Ther (2010) 0.75
Treating hypertension: a new chapter. Do whatever it takes to hit your blood-pressure target. Health News (2003) 0.75
Key articles related to complementary and alternative medicine in cardiovascular disease: part 1. Pharmacotherapy (2010) 0.75
Percutaneous Driveline Fracture Following Implantation of the HeartMate II Left Ventricular Assist Device: How Durable is Driveline Repair? ASAIO J (2017) 0.75
Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. J Heart Lung Transplant (2012) 0.75
Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. Ann Thorac Surg (2012) 0.75
Relationship between obesity and resting energy expenditure in systolic heart failure. J Heart Lung Transplant (2010) 0.75
Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States: executive summary. Ann Thorac Surg (2012) 0.75
A restrictive inflow pattern does not predict implantable cardioverter-defibrillator therapy in primary prevention. Clin Cardiol (2009) 0.75
Impact of Patient Distance From Ventricular Assist Device-Implanting Center on Short- and Long-Term Outcomes. ASAIO J (2017) 0.75
Left Lateral Thoracotomy for Centrifugal Continuous-Flow Left Ventricular Assist Device Placement: An Analysis from the Mechanical Circulatory Support Research Network. ASAIO J (2017) 0.75
Adverse Event Rates Change Favorably Over Time for Patients Bridged With the HeartWare Left Ventricular Assist Device. ASAIO J (2017) 0.75
Effects of hawthorn on the progression of heart failure in a rat model of aortic constriction. Pharmacotherapy (2009) 0.75
Lipid-lowering therapy at hospital discharge after coronary artery bypass grafting. Am J Health Syst Pharm (2002) 0.75
Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States: executive summary. Circ Heart Fail (2012) 0.75
Lack of interaction between the peptidomimetic substrates captopril and cephradine. J Clin Pharmacol (2009) 0.75
Key articles, guidelines, and consensus papers relative to the treatment of dyslipidemias--2005. Pharmacotherapy (2006) 0.75
Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering. Pharmacotherapy (2013) 0.75
Outcomes After Concomitant Procedures with Left Ventricular Assist Device Implantation: Implications by Device Type and Indication. ASAIO J (2016) 0.75